Bank Of America Corp Albireo Pharma, Inc. Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$18.01 - $23.78 $110,005 - $145,248	6,108 Added 97.98%	12,342 $266,000
Q3 2022 Nov 14, 2022	SELL	$16.32 - $26.37 $1.13 Million - $1.82 Million	-69,031 Reduced 91.72%	6,234 $121,000
Q2 2022 Aug 12, 2022	BUY	$18.54 - $37.29 $489,845 - $985,239	26,421 Added 54.09%	75,265 $1.49 Million
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $417,561 - $588,493	-17,442 Reduced 26.31%	48,844 $1.46 Million
Q4 2021 Feb 08, 2022	BUY	$21.19 - $31.29 $1.11 Million - $1.64 Million	52,469 Added 379.74%	66,286 $1.54 Million

Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $80,657 - $106,069	2,948 Added 27.12%	13,817 $431,000
Q2 2021 Sep 13, 2021	BUY	$28.9 - $36.87 $314,114 - $400,740	10,869 New	10,869 $382,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.